Drugs / CoronaVac
CoronaVac
Trials 24
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04551547 | Oct 2020 → Apr 2021 | COVID-19 | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT04383574 | May 2020 → Dec 2021 | COVID-19 | Sinovac Life Sciences Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT04352608 | Apr → Jul 2020 | COVID-19 | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07408297 | May 2022 → Jun 2024 | COVID-19 | Victoria Biomedical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT05087368 | Dec 2021 → Apr 2022 | COVID-19 | D'Or Institute for Research and Education | Unknown | No outcome recorded |
| Phase 2 | NCT04992182 | Jul → Aug 2021 | COVID-19 | Universidad del Desarrollo | Unknown | No outcome recorded |
| Phase 2 | NCT04800133 | May 2021 → Mar 2025 | COVID-19 | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 35 trials · 2 met primary | ||||||
| Phase 3 | NCT05225285 | Jan → Jun 2022 | COVID-19 | Federal University of Espirito Santo | Unknown | No outcome recorded |
| Phase 3 | NCT05668065 | Nov 2021 → Jan 2022 | COVID-19 | Institut Pasteur de Tunis | Completed | No outcome recorded |
| Phase 3 | NCT04992260 | Sep 2021 → May 2023 | COVID-19 | Sinovac Research and Development Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT04651790 | Nov 2020 → Aug 2022 | COVID-19 | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| Phase 3 | NCT04582344 | Sep 2020 → Jun 2022 | COVID-19 | Health Institutes of Turkey | Completed | Met primary |
| Phase 410 trials · 1 met primary | ||||||
| Phase 4 | NCT05165732 | Dec 2022 → Mar 2023 | COVID-19 | Sinovac Research and Development Co., Ltd. | Suspended | No outcome recorded |
| Phase 4 | NCT05303584 | Apr → Jun 2022 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT05148949 | Dec 2021 → Dec 2022 | COVID-19, pulmonary tuberculosis | Jiangsu Province Centers for Disease Control and Prevention | Unknown | No outcome recorded |
| Phase 4 | NCT05057169 | Nov 2021 → Dec 2024 | — | The University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT05499351 | Oct → Dec 2021 | COVID-19 | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT05298800 | Oct 2021 → Dec 2022 | — | Centers for Disease Control and Prevention, China | Unknown | No outcome recorded |
| Phase 4 | NCT04894227 | May 2021 | COVID-19 | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT04801667 | Mar → Oct 2021 | Orthocoronavirinae infectious disease, vaccinia | Hospital do Rim e Hipertensão | Unknown | No outcome recorded |
| Phase 4 | NCT04756830 | Feb → Sep 2021 | COVID-19 | D'Or Institute for Research and Education | Unknown | No outcome recorded |
| Phase 4 | NCT04754698 | Feb 2021 → Nov 2023 | AIDS, COVID-19, rheumatic disorder | University of Sao Paulo General Hospital | Completed | Met primary |
| Phase not applicable2 trials | ||||||
| — | NCT04751695 | Feb → Mar 2021 | — | Izmir Bakircay University | Unknown | No outcome recorded |
| — | NCT04751721 | Feb → Mar 2021 | — | Izmir Bakircay University | Unknown | No outcome recorded |
| Comparator or background therapy18 trials | ||||||
| Phase 0 | NCT05918939 Comparator | Sep 2022 → Aug 2023 | COVID-19 | Dr. Soetomo General Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT05583357 Comparator | Aug → Sep 2022 | COVID-19 | Livzon Pharmaceutical Group Inc. | Unknown | No outcome recorded |
| Phase 0 | NCT05928455 Comparator | May → Oct 2022 | COVID-19, vaccinia | Guangzhou Patronus Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05897190 Comparator | May → Jun 2022 | Orthocoronavirinae infectious disease | Argorna Pharmaceuticals Co., LTD | Completed | No outcome recorded |
| Phase 1/2 | NCT05043259 Comparator | Aug → Nov 2021 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | Met primary |
| Phase 2 | NCT05593042 Comparator | Nov 2022 → Oct 2023 | COVID-19 | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| Phase 2 | NCT05230940 Comparator | Feb 2022 → May 2023 | COVID-19 | Health Institutes of Turkey | Completed | No outcome recorded |
| Phase 2 | NCT04979949 Comparator | Jul 2021 → Mar 2022 | COVID-19 | Health Institutes of Turkey | Completed | No outcome recorded |
| Phase 3 | NCT05428592 Comparator | Apr → Oct 2023 | Orthocoronavirinae infectious disease | AIM Vaccine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05683561 Comparator | Jan → Aug 2023 | COVID-19 | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05508477 Comparator | Jun 2022 → Mar 2023 | COVID-19 | Dr. Soetomo General Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05188677 Comparator | Jun 2022 → Jun 2023 | COVID-19 | Clover Biopharmaceuticals AUS Pty | Completed | No outcome recorded |
| Phase 3 | NCT05077176 Comparator | Oct 2021 → May 2023 | COVID-19 | Health Institutes of Turkey | Completed | No outcome recorded |
| Phase 3 | NCT04942405 Comparator | Jun 2021 → Mar 2023 | COVID-19 | Health Institutes of Turkey | Completed | No outcome recorded |
| Phase 4 | NCT04993365 Comparator | Nov 2021 → Jul 2022 | COVID-19 | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT04952727 Comparator | Aug → Nov 2021 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT04775069 Comparator | May 2021 → Sep 2023 | liver disorder | Humanity & Health Medical Group Limited | Completed | No outcome recorded |
| Phase 4 | NCT04789356 Comparator | Mar → Jul 2021 | COVID-19 | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2024-08-23 | Sinovac Biotech Co., Ltd | Results 最新研究：SINOVAC科兴四价流感疫苗抗体滴度高于国外对照疫苗 sinovac.com ↗ |
| 2024-08-09 | Sinovac Biotech Co., Ltd | Results 研究表明：SINOVAC科兴四价流感疫苗批间一致性好，疫苗品质稳定可靠 sinovac.com ↗
研究结果表明，SINOVAC科兴连续三批商业化规模生产的IIV4具有良好的免疫原性和安全性，且各型别抗体水平相当，产品批间一致性好。 |
| 2023-10-27 | Sinovac Biotech Co., Ltd | Results 研究显示：3-8岁儿童接种2针流感疫苗能获得更佳保护 sinovac.com ↗
在既往未接种过或接种过一剂次流感疫苗的儿童中，接种两剂次IIV4的血清保护率要高于接种一剂次IIV4的血清保护率。 |
| 2021-11-01 | PT Bio Farma | Regulatory Vaksin Covid-19 Bio Farma Aman Diberikan Kepada Anak Usia 6 - 11 Tahun co.id ↗
Vaksin Covid-19 dari Sinovac, Coronavac dan Covid-19 Bio Farma yang diproduksi di Bio Farma, telah mendapatkan persetujuan Izin Penggunaan Darurat (EUA) untuk anak usia 6-11 tahun. |
| 2021-08-09 | Inovio Pharmaceuticals | Regulatory INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate inovio.com ↗
China's Center for Drug Evaluation of the National Medical Products Administration has allowed the initiation of two Advaccine-sponsored open-label, positive-control trials to evaluate the safety, tolerability, and immunogenicity of mixed boosted regimens. |
| 2021-01-11 | PT Bio Farma | Regulatory Vaksin Covid-19 Sudah Mulai Bisa Digunakan di Indonesia co.id ↗
Kepala Badan Pengawas Obat dan Makanan Penny K Lukito (kiri) menyerahkan Sertifikat Emergency Use Authorization (EUA) untuk Vaksin Covid-19 CoronaVac, kepada Direktur Utama Bio Farma, Honesti Basyir, di Jakarta 11 Januari 2021. |
All press releases naming this drug 9 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-08-23 | Sinovac Biotech Co., Ltd | 最新研究：SINOVAC科兴四价流感疫苗抗体滴度高于国外对照疫苗 sinovac.com ↗ |
| 2024-08-09 | Sinovac Biotech Co., Ltd | 研究表明：SINOVAC科兴四价流感疫苗批间一致性好，疫苗品质稳定可靠 sinovac.com ↗ |
| 2023-10-27 | Sinovac Biotech Co., Ltd | 研究显示：3-8岁儿童接种2针流感疫苗能获得更佳保护 sinovac.com ↗ |
| 2021-11-01 | PT Bio Farma | Vaksin Covid-19 Bio Farma Aman Diberikan Kepada Anak Usia 6 - 11 Tahun co.id ↗ |
| 2021-08-20 | PT Bio Farma | Bio Farma Sudah Menerima 15 Juta Dosis CoronaVac dari Total 25 juta Dosis di Bulan Agustus co.id ↗ |
| 2021-08-09 | Inovio Pharmaceuticals | INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate inovio.com ↗ |
| 2021-01-11 | PT Bio Farma | Vaksin Covid-19 Sudah Mulai Bisa Digunakan di Indonesia co.id ↗ |
| 2009-01-20 | Sinovac Biotech Co., Ltd | 中维科（Sinovac Biotech Ltd.）举行2008年工作总结大会 sinovac.com ↗ |
| 2004-12-02 | Sinovac Biotech Co., Ltd | Sinovac Biotech Ltd.被批准在美国证券交易所（AMEX）挂牌交易 sinovac.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 43 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CoronaVac | “A Randomized, Open, Control Phase ⅠV Clinical Trial, to Evaluate One Booster Immunization of Inactivated COVID-19 Vaccine (CoronaVac) or Original Vaccine in Adults Aged 18-45...” NCT05165732 ↗43“One of the vaccines developed, the China-based CoronaVac vaccine (inactivated + aluminum adjuvant vaccine) is a vaccine developed with the inactive method, which is the...” NCT04751721 ↗ “Here we aimed to assess the safety, tolerability, and immunogenicity of a candidate COVID-19 vaccine, CoronaVac, containing inactivated SARS-CoV-2, in children and adolescents...” PMID 34197764 ↗ Jun 2021 “This study will assess safety and immunogenicity of the inactivated vaccine adsorbed against COVID-19 (CoronaVac) in a population of healthy individuals older than 18 years of age.” NCT04756830 ↗ “a third booster dose of SARS-CoV-2 inactivated vaccine (CoronaVac), inactivated quadrivalent influenza vaccine (IIV4), and 23-valent pneumococcal polysaccharide vaccine (PPV23)” PMID 39229259 ↗ Aug 2024 “We did a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial of CoronaVac in healthy adults aged 60 years and older in Renqiu (Hebei, China).” PMID 33548194 ↗ Feb 2021 “CoronaVac vaccine (inactivated + aluminum adjuvant vaccine) is a vaccine developed with the inactive method, which is the classic vaccine production method.” NCT04751695 ↗ “Previous phase I to III clinical trials have shown that the inactivated SARS-CoV-2 vaccine namely CoronaVac has good efficacy, safety, and immunogenicity.” PMID 36441137 ↗ Nov 2022 “The inactivated vaccine CoronaVac has been shown to be safe and immunogenic in a phase 1/2 clinical trial in a pediatric cohort in China.” PMID 36383021 ↗ Nov 2022 “Kidney transplant recipients aged 30-69 y with >30 d of transplantation received two 3 µg intramuscular doses of CoronaVac 28 d apart” PMID 34882589 ↗ Apr 2022 “First dose of Coronavac. Each innoculation dose is 0.5 ml containing 600 SU in-house unit (equals to 3μg) of SARS-CoV-2 antigen.” NCT05668065 ↗ |
| Known as | CoronaVac vaccine | “One of the vaccines developed, the China-based CoronaVac vaccine (inactivated + aluminum adjuvant vaccine) is a vaccine developed with the inactive method, which is the...” NCT04751721 ↗ |
| Known as | Sinovac | “The subjects will be vaccinated with inactivated SARS Cov-2 (Sinovac).” NCT04775069 ↗1“two-doses CoronaVac (Sinovac) vaccine” NCT05230940 ↗ |
| Known as | Sinovac CoronaVac | “two doses of an inactivated SARS-CoV-2 vaccine-Sinovac CoronaVac.” PMID 35605625 ↗ May 2022 |
| Modality | Vaccine | “candidate COVID-19 vaccine, CoronaVac, containing inactivated SARS-CoV-2” PMID 33548194 ↗ Feb 2021 |
| Route | Intramuscular | “Vaccine or placebo was given by intramuscular injection in two doses (days 0 and 28).” PMID 33548194 ↗ Feb 2021 |